185 related articles for article (PubMed ID: 37633269)
21. Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways.
Ho WJ; Erbe R; Danilova L; Phyo Z; Bigelow E; Stein-O'Brien G; Thomas DL; Charmsaz S; Gross N; Woolman S; Cruz K; Munday RM; Zaidi N; Armstrong TD; Sztein MB; Yarchoan M; Thompson ED; Jaffee EM; Fertig EJ
Genome Biol; 2021 May; 22(1):154. PubMed ID: 33985562
[TBL] [Abstract][Full Text] [Related]
22. Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets.
Kocher F; Puccini A; Untergasser G; Martowicz A; Zimmer K; Pircher A; Baca Y; Xiu J; Haybaeck J; Tymoszuk P; Goldberg RM; Petrillo A; Shields AF; Salem ME; Marshall JL; Hall M; Korn WM; Nabhan C; Battaglin F; Lenz HJ; Lou E; Choo SP; Toh CK; Gasteiger S; Pichler R; Wolf D; Seeber A
Clin Cancer Res; 2022 Nov; 28(22):4957-4967. PubMed ID: 36112544
[TBL] [Abstract][Full Text] [Related]
23. The coagulation-related genes for prognosis and tumor microenvironment in pancreatic ductal adenocarcinoma.
Wang D; Cui SP; Chen Q; Ren ZY; Lyu SC; Zhao X; Lang R
BMC Cancer; 2023 Jun; 23(1):601. PubMed ID: 37386391
[TBL] [Abstract][Full Text] [Related]
24. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
25. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy.
Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG
Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038
[TBL] [Abstract][Full Text] [Related]
26. Identifying a baicalein-related prognostic signature contributes to prognosis prediction and tumor microenvironment of pancreatic cancer.
Zhang C; Lei D; Zhou Y; Zhong T; Li X; Ai W; Zheng B; Liu J; Piao Y; Yan Z; Lai Z
Front Immunol; 2023; 14():1223650. PubMed ID: 37575248
[TBL] [Abstract][Full Text] [Related]
27. Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma.
Sinha M; Betts C; Zhang L; Griffith MJ; Solman I; Chen B; Liu E; Tamaki W; Stultz J; Marquez J; Sivagnanam S; Cheung A; Pener D; Fahlman A; Taber E; Lerner K; Crocker M; Todd K; Rajagopalan B; Ware C; Bridge M; Vo J; Dragomanovich H; Sudduth-Klinger J; Vaccaro G; Lopez CD; Tempero M; Coussens LM; Fong L
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36593070
[TBL] [Abstract][Full Text] [Related]
28. A Single-Cell Atlas of Tumor-Infiltrating Immune Cells in Pancreatic Ductal Adenocarcinoma.
Wang H; Chen L; Qi L; Jiang N; Zhang Z; Guo H; Song T; Li J; Li H; Zhang N; Chen R
Mol Cell Proteomics; 2022 Aug; 21(8):100258. PubMed ID: 35718340
[TBL] [Abstract][Full Text] [Related]
29. Single cell RNA-seq reveals the CCL5/SDC1 receptor-ligand interaction between T cells and tumor cells in pancreatic cancer.
Chen K; Wang Y; Hou Y; Wang Q; Long D; Liu X; Tian X; Yang Y
Cancer Lett; 2022 Oct; 545():215834. PubMed ID: 35917973
[TBL] [Abstract][Full Text] [Related]
30. Reshaping the Immune Microenvironment by Oncolytic Herpes Simplex Virus in Murine Pancreatic Ductal Adenocarcinoma.
Zhang L; Wang W; Wang R; Zhang N; Shang H; Bi Y; Chen D; Zhang C; Li L; Yin J; Zhang H; Cao Y
Mol Ther; 2021 Feb; 29(2):744-761. PubMed ID: 33130310
[TBL] [Abstract][Full Text] [Related]
31. Single cell transcriptomic analyses implicate an immunosuppressive tumor microenvironment in pancreatic cancer liver metastasis.
Zhang S; Fang W; Zhou S; Zhu D; Chen R; Gao X; Li Z; Fu Y; Zhang Y; Yang F; Zhao J; Wu H; Wang P; Shen Y; Shen S; Xu G; Wang L; Yan C; Zou X; Chen D; Lv Y
Nat Commun; 2023 Aug; 14(1):5123. PubMed ID: 37612267
[TBL] [Abstract][Full Text] [Related]
32. Single-cell RNA-seq reveals the genesis and heterogeneity of tumor microenvironment in pancreatic undifferentiated carcinoma with osteoclast-like giant-cells.
Wang X; Miao J; Wang S; Shen R; Zhang S; Tian Y; Li M; Zhu D; Yao A; Bao W; Zhang Q; Tang X; Wang X; Li J
Mol Cancer; 2022 Jun; 21(1):133. PubMed ID: 35733218
[TBL] [Abstract][Full Text] [Related]
33. Distinct Stromal and Immune Features Collectively Contribute to Long-Term Survival in Pancreatic Cancer.
Sadozai H; Acharjee A; Eppenberger-Castori S; Gloor B; Gruber T; Schenk M; Karamitopoulou E
Front Immunol; 2021; 12():643529. PubMed ID: 33679807
[No Abstract] [Full Text] [Related]
34. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.
Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J
Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257
[TBL] [Abstract][Full Text] [Related]
35. TGFβ-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
Perez-Penco M; Weis-Banke SE; Schina A; Siersbæk M; Hübbe ML; Jørgensen MA; Lecoq I; Lara de la Torre L; Bendtsen SK; Martinenaite E; Holmström MO; Madsen DH; Donia M; Ødum N; Grøntved L; Andersen MH
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600556
[TBL] [Abstract][Full Text] [Related]
36. High-dimensional single-cell analysis unveils distinct immune signatures of peripheral blood in patients with pancreatic ductal adenocarcinoma.
Pan Y; Gao J; Lin J; Ma Y; Hou Z; Lin Y; Wen S; Pan M; Lu F; Huang H
Front Endocrinol (Lausanne); 2023; 14():1181538. PubMed ID: 37347110
[TBL] [Abstract][Full Text] [Related]
37. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
38. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.
Oberg HH; Grage-Griebenow E; Adam-Klages S; Jerg E; Peipp M; Kellner C; Petrick D; Gonnermann D; Freitag-Wolf S; Röcken C; Sebens T; Vogel I; Becker T; Ebsen M; Kabelitz D; Wesch D; Sebens S
Pancreatology; 2016; 16(6):1069-1079. PubMed ID: 27424476
[TBL] [Abstract][Full Text] [Related]
39. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
[TBL] [Abstract][Full Text] [Related]
40. Interleukin 35 Expression Correlates With Microvessel Density in Pancreatic Ductal Adenocarcinoma, Recruits Monocytes, and Promotes Growth and Angiogenesis of Xenograft Tumors in Mice.
Huang C; Li Z; Li N; Li Y; Chang A; Zhao T; Wang X; Wang H; Gao S; Yang S; Hao J; Ren H
Gastroenterology; 2018 Feb; 154(3):675-688. PubMed ID: 28989066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
